Neurogen Selects William Koster to Be Chief Executive Officer
- Has Comprehensive Scientific Background with 30 Years Experience -
BRANFORD, Conn., Sep 10, 2001 /PRNewswire via COMTEX/ -- Neurogen Corporation (Nasdaq: NRGN chart, msgs), one of the nation's leading drug discovery and development companies, today announced that its board of directors has appointed Dr. William H. Koster, a veteran pharmaceutical executive, to be its Chief Executive Officer. Koster, 57, succeeds Harry Penner, 56, who previously announced that he would retire when a successor was named. Koster's appointment is effective immediately.
Dr. Koster has more than 30 years experience developing and commercializing drugs with Bristol-Myers Squibb Company (BMS) and E.R. Squibb & Sons, Inc., which merged with Bristol-Myers in 1989. In his most recent position, Dr. Koster was Bristol-Myers' Senior Vice President for Science and Technology Strategy and Acquisition heading up the company's external science and technology, scientific intelligence, intellectual property strategy and science policy functions. He was based at Bristol-Myers' headquarters in Princeton, N.J. snip...
siliconinvestor.com |
